TIDMONC
Oncimmune Holdings PLC
15 December 2020
15 December 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Publication of autoantibody profiles for response prediction to
Rheumatoid Arthritis treatment
Collaboration with Roche Pharmaceuticals and University Medical
Center Utrecht
demonstrates the utility of autoantibodies in Methotrexate and
Tocilizumab treatment selection
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, is pleased to announce the publication by
PLOS ONE of a study, supported by the Oncimmune's ImmunoINSIGHTS
team, which analysed autoantibodies in patients with newly
diagnosed Rheumatoid Arthritis (RA) who were treated with either
Tocilizumab or Methotrexate monotherapy. This work significantly
expanded the biomarkers commonly measured in RA patients to develop
a detailed picture of the immune response to the disease and its
treatment.
The aim of the study was to develop a set or panel of predictive
biomarkers to identify an early response in RA patients to
Methotrexate or Tocilizumab, Roche's interleukin-6 (IL-6) receptor
inhibitor.
The study titled 'Comprehensive exploratory autoantibody
profiling in patients with early Rheumatoid Arthritis treated with
Methotrexate or Tocilizumab', is available online .(1)
Rheumatoid Arthritis is an autoimmune disorder primarily of
joints, that causes long-term damage. The current diagnostic tests
measure Rheumatoid Factor, which is typically elevated in 60-90% of
patients with the autoimmune condition. Successful validation of a
novel autoantibody panel that is predictive of treatment response
would be a major step forward in the management of this
debilitating disease.
ImmunoINSIGHTS, Oncimmune's autoantibody profiling technology
and service business, continues to work in partnership with therapy
developers to generate, actionable, value-adding insights for their
drug development programmes.
Dr Adam M Hill, CEO of Oncimmune said: " Rheumatoid Arthritis is
a debilitating, chronic disease where there remains a substantial
unmet need in ensuring patients receive the right disease modifying
treatment as early as possible. This work, in collaboration with
colleagues at Roche and UMC Utrecht, clearly demonstrates the power
of our SeroTag(TM) autoantibody discovery platform in identifying
biomarkers able to predict response to a selection of treatments
for Rheumatoid Arthritis. This predictive capability presents an
opportunity to develop and validate novel autoantibody panels for
patient stratification in trials and the clinic. "
(1)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0241189
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies. The key
to improving cancer survival is early detection and better
selection for therapy. As a company, we are driven by our passion
to improve cancer survival and to give people extra time.
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue from its portfolio of diagnostic products to detect
early-stage cancer and a contract discovery and development
service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners .
Oncimmune's ImmunoINSIGHTS platform enables life-science
organisations to optimise drug development and delivery, leading to
more effective targeted as well as safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
For more information, visit www.oncimmune.com
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is SeroTag?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID disease-specific
stratification panels-precision medicine tools which are enabling
patient and disease stratification and support therapeutic
development.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRATIBFTMTTBBAM
(END) Dow Jones Newswires
December 15, 2020 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024